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Management
of Migraine
Migraine is a complex neurovascular
disease characterised by episodic
attacks of severe headache
accompanied by autonomic and
neurological symptoms. Two types
of migraine have been identified:
(1) common migraine, or migraine
without aura, occurring in about
70% of migraine patients
(migraineurs); (2) classic migraine,
or migraine with aura. In the latter
case, aura symptoms are usually
manifested as visual hallucinations
such as flashing lights, zig-zag lines
or blind spots, although sensory
and motor dysfunction may also
occasionally occur.
Migraineurs are defined as those
individuals who have had at least two
attacks of classic migraine, or at least
five attacks of common migraine. Thus,
any individual can suffer an isolated
migraine attack without being a
migraine patient. On the other hand,
patients suffering from at least one
attack during the previous year are
termed active migraineurs. The
epidemiology of migraine is similar
across western countries and is highly
dependent on age and gender. About
10% of the general population are
active sufferers. However, several
studies have shown that migraine is
two to three times more prevalent in
Diagnosis
Migraine is a common clinical
disorder that continues to be highly
under-recognized. Diagnosis is difficult
because it is hard to elicit precise
information from a patient who is
trying to translate symptoms into
words, the symptoms are somewhat
similar to those of tension headaches,
and the manifestation of attacks
exhibits considerable inter- and intra-
patient variability. The situation is
further complicated by the fact that
there are no biological markers to
confirm diagnosis.
Based on the recommendations of
the International Headache Society, a
number of diagnostic criteria for
migraine have been put forward (Table
1). These guidelines should all be taken
into account when formulating a
patient interview with the aim to
obtain an accurate headache history of
the sufferer. Such history-taking plays a
key role in migraine diagnosis and
should thoroughly address all the
relevant criteria. During the interview,
it is important to look out for and
recognise certain patterns that are
typical of migraine attacks. Thus, the
patient should be questioned about:
• Family history of migraine
• Abatement of the headache with
sleep
• Perimenstrual or periovulation
timing of migraine attacks
• Stimulation of attack by sustained
exertion
• Consistent precipitation of
headaches by reliable triggers (Table
2).
Patient interview alone is not
always sufficient to make a definite
diagnosis of migraine. In such cases, it
is essential for the patient to undergo a
physical examination in order to
eliminate the possibility that there is a
more serious underlying cause of the
headaches. Features which raise
concern and which require immediate
referral include:
1) a first severe headache of rapid
onset
2) a marked change from a previously
stable long-standing headache
pattern
adult females than it is in adult males,
with females in their 40’s having the
highest incidence. In active
migraineurs, the median attack
frequency is 1.5 per month and the
median duration of attacks is just under
one day although attacks lasting
several days are known to occur. Thus,
there is enormous variation from
patient to patient as well as from
attack to attack.
Migraine attacks can have profound
effects on the day-to-day life and the
well-being of the sufferer. Migraineurs
suffering from frequent, debilitating
attacks may have to absent themselves
from work, or may experience reduced
productivity even when attempting to
perform normal daily activities. In
addition, the impact of migraine
stretches beyond the time of the actual
attack, since some patients may have
to curtail their activities to avoid
situations that may trigger an attack.
Reduction in the burden of migraine
may be achieved through accurate
diagnosis, assessment of the disability
experienced by the individual and
appropriate, well-executed treatment
strategies. Moreover, the goal of the
treatment should be not only to relieve
pain, but to restore the patient’s ability
to function normally as rapidly as
possible.
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3) a new onset of headache after age
50
4) the precipitation of severe head
pain by bending down, exertion or
coughing
5) the presence of systemic symptoms
such as fever, malaise, myalgia or
weight loss.
Pharmacological Management
of Migraine
Traditionally, the pharmacological
management of migraine has focussed
on two major approaches: symptomatic
treatment and prophylactic therapy.
Symptomatic treatment
The objective of symptomatic
treatment is to reduce the intensity and
duration of pain and its associated
symptoms, whilst optimising the
patient’s ability to function normally.
Treatment of attacks generally involves
the use of one or a combination of the
following classes of drugs: simple
analgesics, nonsteroidal anti-
inflammatory drugs, antiemetics,
narcotic analgesics, ergot derivatives
and serotonin(1)-agonists. The choice
of the medication depends on a number
of patient factors (Table 3), and on the
treatment strategy selected.
There are two major strategies for
the treatment of migraine: step-care
and stratified care. In step-care, all
patients begin at the bottom of the
therapeutic pyramid, starting with an
inexpensive simple analgesic. After an
appropriate trial, if treatment is
unsuccessful, therapy is escalated until
patients get the treatment that is
successful. In stratified-care, the
treatment of the patient is immediately
matched with the severity of the
condition. Thus, the patient’s treatment
needs must be identified by assessing
the degree of disability experienced by
the patient. In mild attacks, the
patient can proceed with daily
activities with only very minimal
disruption; in moderate attacks, the
patient experiences moderate
impairment in normal activities; in
severe attacks, the patient is unable to
proceed with daily activities and
experiences impaired efficiency in any
capacity due severe discomfort; in
ultra-severe cases, there is prolonged
inability to function in any capacity.
Table 4 summarises the various
drugs commonly used to treat mild and
moderate attacks of migraine, and gives
the initial dose that is generally used
to treat migraine attacks in adult
patients. Milder migraine headaches
often respond to paracetamol or
aspirin, but since peristalsis is often
reduced during attacks the medications
may fail to be sufficiently absorbed to
be effective. Therefore, effervescent or
dispersible formulations are preferable.
Other non-steroidal anti-inflammatory
drugs (NSAIDs), such as naproxen,
mefenamic acid and tolfenamic acid
have been used in the treatment of
moderate migraine attacks, but their
use may be restricted by their
gastrointestinal side effects. In
addition, oral anti-emetics, such as
metoclopramide or prochlorperazine,
are usually required as adjunctive
therapy in order to relieve the
symptoms of nausea associated with
migraine. If vomiting is a problem,
Table 1: Diagnostic criteria for Migraine
I. Migraine without aura
1) At least five attacks fulfilling criteria (2) to (4)
2) Headache attacks, untreated or unsuccessfully treated, lasting 4 to 72
hours
3) At least two of the following headache characteristics:
a) unilateral location
b) pulsation
c) moderate to severe pain intensity
(interferes with or prohibits daily activities)
d) aggravation by motion (e.g. walking up stairs or similar routine
activity)
4) At least one of the following associated symptoms:
a) nausea and /or vomiting
b) photophobia
c) phonophobia
d) osmophobia (aversion to odours)
5) No evidence of related organic disease
II. Migraine with aura
1) At least two attacks fulfilling criteria (2) to (5)
2) One or more fully reversible aura symptoms
(usually manifested as visual disturbances)
3) At least one aura symptom develops gradually over > 4 minutes, or two or
more symptoms develop in rapid succession
4) Duration of aura symptoms is 4 to 60 minutes
5) Headache follows aura within one hour, or begins before or
simultaneously with aura
Table 3: Factors influencing
the choice of
medication for acute
migrane attacks
1) Severity of the attack (mild,
moderate, severe)
2) Presence or absence of vomiting
3) Time from onset of pain to peak
pain level
4) Comorbid medical conditions
5) Concomitant use of other
medications
6) Adverse effects of the drug
• Stress/strain/emotional
disturbances
• Light stimulation/glare
• Lack of sleep, fatigue
• Excessive sleep
• Menstrual periods
• Fasting
• Alcohol
• Specific foods, such as chocolate,
caffeine, aged cheeses
• Medications, such as oral
contraceptives, nitroglycerine
Table 2: Precipitating factors
of migraine attacks.
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Table 4: Commonly used medications
for the treatment of migraine of different severity.
Drug Proprietary name Initial Oral Adult Dose
I. Mild attacks
Paracetamol Panadol® (Sterling Health) 1000 mg
Aspirin Aspro® (Roche) 500-1000 mg
Ibuprofen Nurofen® (Crookes Healthcare) 400 mg
Naproxen sodium Naprosyn® (Roche) 500 mg
Metoclopramide Maxolon® (SmithKline Beecham) 10 mg
Domperidone Motilium® (Janssen) 20 mg
Dimenhydrinate Dramamine® (Searle) 100 mg
II. Moderate attacks
Ibuprofen Nurofen® (Crookes Healthcare) 400 mg
Naproxen sodium Naprosyn® (Roche) 500mg
Mefenamic acid Ponstan® (Parke-Davies) 500 mg
Tolfenamic acid Clotam® (GEA Ltd.) 200 mg
Ergotamine Migril ® (GlaxoWellcome) 1-2 mg
Sumatriptan Imigran® (GlaxoWellcome) 50-100 mg
Zolmitriptan Zomig® (Zeneca) 2.5-5 mg
Combination drugs:
Paracetamol+
codeine+caffeine Solpadeine® (Smithkline Beecham) 2 tablets
Paracetamol+codeine Migraleve® (Pfizer) 2 tablets
Aspirin+codeine Codis® (Reckitt & Colman) 2 tablets
domperidone or prochlorperazine may
be administered rectally. Oral analgesic
preparations containing
metoclopramide constitute a
convenient therapeutic alternative.
Combination medications containing
paracetamol or aspirin with codeine
and/or caffeine may be used in patients
who do not respond to simple analgesic
therapy. However, such products should
be used intermittantly and on a short-
term basis in order to preclude rebound
headache.
Oral ergotamine has been used in
the management of migraine for many
years. However, its use is limited by a
number of factors. Firstly, it is
associated with variable bioavailability
due to erratic absorption. It has to be
taken early during an attack to prevent
vomiting and may actually sometimes
cause nausea, vomiting, abdominal
pain and muscular cramps as side
effects. In addition, it cannot be
prescribed in conjunction with
commonly used prophylactic migraine
treatments such as beta-blockers. To
avoid habituation, the frequency of
administration of ergotamine should be
limited to no more than twice a month,
treatment should not be repeated at
intervals of less than four days and it
should not be given prophylactically.
The newer triptan drugs, mainly
sumatriptan and zolmitriptan, have
today become the drugs of choice for
the treatment of moderate migraine
attacks which are unresponsive to
NSAID therapy. These agents are highly
selective serotonin 5HT1B/1D receptor
agonists inhibiting cranial vasodilation
and neurogenic inflammation.
Zolmitriptan, which has improved oral
bioavailability relative to sumatriptan,
also  crosses the blood brain barrier
and has central effects, inhibiting the
transmission of pain impulses. Unlike
ergotamine, both sumatriptan and
zolmitriptan are effective whether
taken early or late after the onset of
headache; however, sumatriptan is not
effective during the aura phase
preceding headache onset. Another
advantage of the triptans over
ergotamine is that they can be
prescribed concomitantly with beta-
blockers. However, the triptans should
not be co-administered with
ergotamine because of increased risk of
vasospasm; in fact, ergotamine should
be avoided for at least six hours after
administration of either of the triptans,
while sumatripan and zolmitriptan
should be avoided for 24 hours and 6
hours respectively following the use of
ergotamine. Side-effects associated
with the triptans include nausea,
dizziness, drowsiness, heat sensations,
tingling, weakness, transient increases
in blood pressure and heaviness,
tightness or pressure in the neck,
throat limbs or chest. Thus, these
agents are contra-indicated in patients
suffering from cardiac diseases or
uncontrolled hypertension. Also, like
ergotamine, they are contraindicated
during pregnancy.
Severe migraine attacks may require
parenteral administration of
dihydroergotamine or triptan drugs, as
well as adjunctive parenteral
medications. Hence the patient should
be referred to a physician’s clinic or, in
ultra-severe cases, to the hospital
emergency department.
Prophylactic treatment
The main objective of prophylactic
therapy is the reduction of the
frequency, duration and intensity of
attacks by at least 50% using the least
amount of medication with the fewest
side effects. Such therapy should be
considered for patients suffering from
two or more attacks per month, which
do not respond to symptomatic
treatment. When selecting a medication
for prophylaxis, it is important to take
into account the possible presence of
co-morbid conditions and the drugs’
side-effects. Agents used include:
1) beta-blockers without instrinsic
sympathomimetic activity, such as
atenolol, propranolol and
metoprolol but not pindolol
(contraindicated in patients with
asthma, chronic obstructive
pulmonary disease, peripheral
vascular disease, heart failure and
diabetes mellitus and in pregnancy)
2) tricyclic antidepressants, such as
amitriptylene (contraindicated in
patients with glaucoma and cardiac,
kidney, liver, prostate or thyroid
disease)
3) calcium-channel blockers, such as
verapamil, nifedipine and
flunarizine (contraindicated in
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pregnancy, and in patients with
hypotension, arrhythmias,
congestive heart failure)
4) pizotifen, which however may cause
fatigue, drowsiness and weight gain
5) sodium valproate, which however
has occasionally been associated
with severe hepatic and pancreatic
toxicity
6) NSAIDs, which however should only
be used intermittently, for example
to prevent perimenstrual attacks, in
view of their gastrointestinal side
effects.
Except in the most resistant cases,
it is recommendable to use only a
single prophylactic agent at any time.
Prophylactic therapy should not be
expected to work immediately and may
take several weeks before an effect is
observed. Treatment should be started
at a low dose, and the dosage
subsequently increased to the
maximally effective tolerable dose. The
therapy should be continued for an
adequate period, and then withdrawn
gradually to minimise the risk of
rebound headaches.
Conclusion
Pharmacists are in an excellent
position to educate patients on the
nature of migraine and its management
and hence improve patient compliance.
They may help patients to understand
the actions of their medications and
the possible adverse effects, drug
interactions and contraindications (e.g.
pregnancy) associated with their
therapy. They may assess the degree of
patient compliance to prescribed
prophylactic medications. Pharmacists
may also offer advice to patients on
non-drug therapies such as relaxation
techniques.  Another important area is
the identification and avoidance of
triggering factors including specific
foods, and hence the provision of
dietary advice.
These factors make the pharmacist a
key role-player in the provision of
pharmaceutical care in the prevention
and treatment of migraine.  ✱
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Management of Migraine
Assessment Questions:
6. What is the normal initial dose of
sumatriptan in the treatment of
migraine in adults?
a) 0.1 mg
b) 1 mg
c) 10 mg
d) 100 mg
7. Which of the following drugs is used
in the prevention of migraine attacks?
a) amitriptylene
b) propranolol
c) pizotifen
d) all of the above
8. Which of the following beta-blockers
cannot used as a migraine
prophylactic agent?
a) atenolol
b) pindolol
c) propranolol
d) metoprolol
9. Which of the following drugs can be
used concomitantly with beta-
blockers?
a) zolmitriptan
b) ergotamine
c) verapamil
d) dihydroergotamine
10.Which of the following foods is known
to be a migraine triggering factor?
a) carrots
b) cheese
c) potato
d) rice
1. Which of the following symptoms is
not normally associated with
migraine?
a) headache
b) nausea
c) vomiting
d) diarrhoea
2. In migraine, head pain is not
accompanied by:
a) photophobia
b) phonophobia
c) xenophobia
d) osmophobia
3. Migraineurs are defined as those
individuals who have had at least
a) two
b) three
c) four
d) five
attacks of common migraine.
4. The highest incidence of migraine
occurs in
a) young boys
b) young girls
c) adult females
d) adult males
5. What is the normal initial dose of
zolmitriptan in the treatment of
migraine in adults?
a) 0.25 mg
b) 2.5 mg
c) 25 mg
d) 250 mg
Select only ONE option in each question
by ticking the respective box
on the Response Sheet (page 39).
Completion of Assessment Questions
following this article entitles members
to one credit towards C.E. requirement.
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15.Which of the following drugs can be
used to treat migraine in pregnant
women?
a) sumatriptan
b) ergotamine
c) zolmitriptan
d) none of the above
16.Which of the following factors
should be taken into account when
selecting the appropriate
antimigraine therapy for a patient?
a) severity of the attack
b) presence or absence
of vomiting
c) presence of
concomitant medical
conditions
d) all of the above
17.What is the main reason for
combination products containing
NSAIDs to be used only
intermittantly?
a) prolonged use may give
rise to rebound
headache
b) the patient may become
tolerant  to the
medication
c) the patient may develop
an allergic reaction to the drug
11.A migraine attack may be triggered
by:
a) stress
b) excessive sleep
c) insufficient sleep
d) all of the above
12.Which of the following anti-emetics
is generally administered rectally in
migraine patients experiencing
vomiting?
a) metoclopramide
b) domperidone
c) dimenhydrinate
d) none of the above
13.Which of the following drugs is used
in the treatment of migraine
attacks?
a) nalidixic acid
b) tolfenamic acid
c) ascorbic acid
d) none of the above
14.Which of the following drugs would
be preferable in the first-line
treatment of a mild migraine attack
in an asthmatic individual?
a) ibuprofen
b) paracetamol
c) atenolol
d) naproxen
d) the high cost associated
with continuous use of such
products
18.Which of the following classes of
drugs are not used in the
management of migraine?
a) beta-receptor blocking
agents
b) histamine-receptor
agonists
c) serotonin(1)-receptor
agonists
d) none of the above
19.Which of the following symptoms is
not a common adverse effect
associated with the triptan drugs?
a) drowsiness
b) warm sensation
c) nausea
d) skin rash
20.Amitriptylene should not be used to
prevent migraine in patients with
a) cardiac disease
b) thyroid disease
c) glaucoma
d) all of the above
